Healthcare -
Biotechnology - NASDAQ - US
$ 18.27
-3.43 %
$ 895 M
Market Cap
-10.42
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Enliven Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 105 M |
| Operating Income | -105 M |
| Other Expenses | -15.5 M |
| Net Income | -89 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GROSS PROFIT | ||||||||
| Cost Of Revenue | 0 | 0.3 | 0.6 | 99 K | 97 K | 33 K | 0 | 0 |
| Gross Profit | 0 | (0.3) | (0.6) | 99 K | 97 K | 33 K | 0 | 0 |
| OPERATING INCOME | ||||||||
| Operating Expenses | 104.6 | 83.5 | 38.8 | 24.8 | 9.3 | 24.1 | 10.7 | 8.9 |
| Selling, General and Administrative Expenses | 23.8 | 19.0 | 7.8 | 4.3 | 1.1 | 5.1 | 2.4 | 1.0 |
| Research and Development Expenses | 80.5 | 64.6 | 31.0 | 20.5 | 8.2 | 19.0 | 8.2 | 7.9 |
| Operating Income | (104.6) | (83.5) | (38.8) | (24.8) | (9.3) | (24.1) | (10.7) | (8.9) |
| PRE-TAX INCOME | ||||||||
| Interest Income Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income | 15.3 | 11.9 | 1.1 | 22 K | (9.6) | 0.7 | (0.7) | 9.1 |
| Pre-Tax Income | (89.3) | (71.6) | (37.7) | (24.7) | (19.0) | (23.5) | (11.3) | 0.2 |
| NET INCOME | ||||||||
| Tax Provision | (0.2) | 0 | 88 K | 22 K | 31 K | 0.7 | (0.8) | 0.2 |
| Net Income | (89.0) | (71.6) | (37.8) | (24.7) | (18.9) | (23.5) | (11.3) | 0 |
| EPS | 1.89 | 2.01 | 6.03 | 3.17 | 14.1 | 5.43 | 2.62 | 0 |